Related Experiment Videos
Megatrials of hormonal replacement therapy
1Sydney Menopause Centre, Royal Hospital for Women, Randwick, New South Wales, Australia.
Drugs & Aging
|June 2, 1998
Summary
Estrogen replacement therapy offers benefits to postmenopausal women, but concerns about cancer risk persist. Ongoing large-scale trials are crucial for clarifying hormone therapy
Area of Science:
- Reproductive endocrinology
- Oncology
- Cardiovascular disease research
Background:
- Estrogen replacement therapy (ERT) is valuable for postmenopausal women.
- Patient reluctance exists due to fears of increased uterine and breast cancer risk.
- Previous epidemiological studies lack clarity on hormone therapy's impact on breast cancer.
Purpose of the Study:
- To determine the role of hormone therapy in breast cancer development.
- To assess the impact of hormone therapy on cardiovascular disease.
- To provide evidence-based guidance for physicians regarding hormone therapy use.
Main Methods:
- Initiation of ambitious prospective trials.
- Inclusion of major studies like the Women's Health Initiative, PEPI Trial, HERS, WISDOM, and Million Women Study.
- Ongoing data collection and analysis.
Main Results:
- The Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial demonstrated substantial benefits of hormone replacement therapy.
- The PEPI Trial was not sufficiently powered to determine effects on breast cancer incidence.
- Results from other major prospective trials are pending.
Conclusions:
- Completion and publication of ongoing prospective studies are imperative.
- Evidence from these trials is necessary for informed clinical decision-making.
- Physicians require definitive data to advise patients appropriately on hormone therapy.